Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).

Orforglipron reduced apnea-hypopnea index at 52 weeks by 13.2 events/h more than placebo in adults with moderate to severe OSA not on positive airway pressure.

• Why it matters: Obstructive sleep apnea is linked to impaired quality of life and cardiometabolic risk, and effective oral options for moderate to severe disease are needed beyond existing therapies.
• What they did: In two 52-week, phase 3, multicenter, double-blind randomized trials in adults with BMI ≥27, participants received once-daily orforglipron (max tolerated dose equivalent to 9-, 14.5-, or 17.2-mg tablets) or placebo, with AHI change as the primary endpoint.
• The result: In trial 1 (n=363) and trial 2 (n=349, on positive airway pressure), AHI improvements favored orforglipron at 52 weeks (differences -13.2 and -12.0, both P<.001), with gastrointestinal events most common.

AI summary of the abstract · may contain errors · not medical advice · read the paper.